Biotech entity
All 1 tracked stories fall under one category: pharma. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.9.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 1 Biotech story that mention Spectral AI, Inc., all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Earnings Release
Official announcement of Q4 and FY2025 results and introduction of 2026 guidance.
Guidance Period Start
Commencement of the 2026 fiscal year covered by the new revenue outlook.
Fiscal Year End
Spectral AI closes the year with $15.4M in cash and $19.7M in R&D revenue.
Spectral AI reported full-year 2025 R&D revenue of $19.7 million, driven by its DeepView AI-driven wound diagnostic platform. The company ended the year with $15.4 million in cash and provided its first revenue outlook for 2026, signaling a transition toward commercial scale.
Spectral AI, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
